Centessa Pharmaceuticals (CNTA) Gains from Investment Securities (2022 - 2026)
Centessa Pharmaceuticals (CNTA) reported Gains from Investment Securities of $3.7 million for Q1 2026, down 16.77% year-over-year from $4.4 million in Q1 2025, and up 1976.14% on a QoQ basis from $176000.0 in Q4 2025.
Centessa Pharmaceuticals (CNTA) has 5 years of Gains from Investment Securities data on file, last reported at $3.7 million in Q1 2026.
- Quarterly Gains from Investment Securities fell 16.77% year-over-year to $3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 58.23% YoY) and the FY2025 annual result came in at $4.8 million, down 9.91% from the prior year.
- Gains from Investment Securities advanced to $3.7 million in Q1 2026 per CNTA's latest filing, from $176000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $9.7 million in Q1 2023 and bottomed at -$206000.0 in Q4 2022.
- The 5-year median for Gains from Investment Securities is $1.3 million (2024), against an average of $2.3 million.
- The widest annual swing landed in 2025, when Gains from Investment Securities plunged 96.38%; it then decreased 16.77% in 2026.
- Tracing CNTA's Gains from Investment Securities over 5 years: stood at -$206000.0 in 2022, then jumped by 4814.08% to $9.7 million in 2023, then tumbled by 83.66% to $1.6 million in 2024, then slumped by 88.91% to $176000.0 in 2025, then surged by 1976.14% to $3.7 million in 2026.
- Per Business Quant, the three latest CNTA Gains from Investment Securities figures stand at $3.7 million (Q1 2026), $176000.0 (Q4 2025), and $125000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Centessa Pharmaceuticals | 6.12 Bn | 6.12 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.65 Mn |
| Mar 31, 2026 | 3.65 Mn |
| Dec 31, 2025 | 176,000.00 |
| Dec 31, 2025 | 176,000.00 |
| Sep 30, 2025 | 125,000.00 |
| Sep 30, 2025 | 125,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Jun 30, 2025 | 100,000.00 |
| Mar 31, 2025 | 4.39 Mn |
| Mar 31, 2025 | 4.39 Mn |
| Dec 31, 2024 | 1.59 Mn |
| Dec 31, 2024 | 1.59 Mn |
| Sep 30, 2024 | 970,000.00 |
| Sep 30, 2024 | 970,000.00 |
| Jun 30, 2024 | 2.76 Mn |
| Jun 30, 2024 | 2.76 Mn |
| Mar 31, 2023 | 9.71 Mn |
| Mar 31, 2023 | 9.71 Mn |
| Dec 31, 2022 | -206,000.00 |
| Dec 31, 2022 | -206,000.00 |